VEGFA and ovarian hyperstimulation syndrome: Results of a study conducted in patients at high-risk for OHSS showed that doses of 2.5 mg, 5.0 mg, and 7.5 mg daily, orally administered for 5 consecutive days after oocyte retrieval, are able to decrease serum estrogen and VEGF levels.